Tag: Seattle Genetics

The global biotechnology company Seattle Genetics earlier today confirmed development and icencing agreement with Immunomedics. Under the terms of the agreement, Seattle Genetics receives...

Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...

The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics)  in combination with nivolumab (Opdivo; Bristol-Myers Squibb...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...

This week, Seattle Genetics and Takeda Pharmaceutical Co. confirmed that enrollment in the ECHELON-2 clinical trial, a global phase III randomized trial evaluating brentuximab vedotin...

In a pre-conference announcement before the start of 10th International Symposium on Hodgkin Lymphoma (ISHL) taking place at the Gürzenich in Cologne, Germany, October 22-25,...

The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...

A phase III study called CASCADE, designed to evaluate Seattle Genetics' vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) or decitabine (Dacogen) has...

With two approved antibody-drug conjugates and a large number of  ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...